Infectious Disease Pharmacokinetics Laboratory

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

Lua error in package.lua at line 80: module 'strict' not found.

Infectious Disease Pharmacokinetics Laboratory
Type Research/Clinical Laboratory
Headquarters University of Florida
Location
Director
Dr. Charles Peloquin
Website Official website

The Infectious Disease Pharmacokinetics Laboratory (IDPL) is a research facility that is affiliated with the College of Pharmacy at the University of Florida.[1]

Overview

IDPL focuses on the treatments for infections that include HIV, tuberculosis, and other serious infections. This facility provides therapeutic drug monitoring (TDM) using high-performance liquid chromatography and gas chromatography. IDPL has been in existence for two decades and has developed individualized drug regimens by monitoring a patient’s blood plasma or serum for target drug concentrations and then interpreting these results and advising physicians how to adjust a drug’s dosage to achieve an optimal outcome. This interdisciplinary method allows IDPL to assess each patient’s ability to absorb, metabolize and excrete drugs, which then enables them to recommend customized drug dosages based upon these pharmacokinetic factors as well as the severity of the patient’s infection. IDPL primarily focuses on tuberculosis, but they also develop drug regimens for cancer patients with fungal infections, and people with HIV.

The Infectious Disease Pharmacokinetics Laboratory also serves as a national reference center for the determination of serum concentrations for the antimycobacterial, antifungal, and anti-HIV drugs, as well as linezolid.

Leadership

The director is Dr. Charles Peloquin who has been leading this facility for over 20 years. This facility is unique in that it provides finely detailed interpretations of results as applied to adjusting the drug regimens of individual patients. Dr. Peloquin's research efforts focuses on therapeutic drug monitoring and clinical trials for patients with advanced mycobacterial diseases.[2][3][4][5]

References

External links